CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Olumiant baricitinib Alopecia areata, severe Active
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older Active
TBC clindamycin plus benzoyl peroxide and adapalene acne vulgaris Active
TBC ivosidenib Acute myeloid leukemia (AML) Active
Keytruda pembrolizumab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
NA icatibant Hereditary Angioedema Active
Livmarli maralixibat Alagille syndrome Active
Leqvio inclisiran Primary hypercholesterolemia Active
Dificid fidaxomicin Clostridium difficile infection Active
Leqvio inclisiran Primary hypercholesterolemia Active
Last Updated : May 3, 2024